TESARO (NASDAQ:TSRO)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Monday, November 20th. They currently have a $158.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 89.61% from the company’s current price.
A number of other equities analysts have also recently weighed in on TSRO. Robert W. Baird restated a “neutral” rating and set a $140.00 price objective (down from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Jefferies Group set a $124.00 target price on shares of TESARO and gave the stock a “hold” rating in a report on Thursday, August 17th. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 target price on shares of TESARO in a report on Thursday, August 10th. Credit Suisse Group set a $190.00 target price on shares of TESARO and gave the stock a “buy” rating in a report on Friday, August 18th. Finally, BidaskClub raised shares of TESARO from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. TESARO has a consensus rating of “Buy” and an average price target of $159.39.
TESARO (NASDAQ:TSRO) traded down $1.43 during trading hours on Monday, reaching $83.33. 518,083 shares of the company’s stock traded hands, compared to its average volume of 1,017,733. TESARO has a 12 month low of $79.03 and a 12 month high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm had revenue of $142.77 million during the quarter, compared to analysts’ expectations of $130.57 million. During the same period in the previous year, the business posted ($1.72) EPS. The business’s revenue was up 740.3% compared to the same quarter last year. equities research analysts expect that TESARO will post -8.17 earnings per share for the current year.
In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the transaction, the senior vice president now directly owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James O. Armitage sold 10,000 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $1,171,300. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,421 shares of company stock worth $1,312,175. 40.50% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in TSRO. Exane Derivatives purchased a new position in TESARO in the 3rd quarter valued at $106,000. Botty Investors LLC purchased a new position in TESARO in the 2nd quarter valued at $140,000. Nordea Investment Management AB purchased a new position in TESARO in the 2nd quarter valued at $167,000. Oppenheimer Asset Management Inc. grew its position in TESARO by 3,042.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the last quarter. Finally, Toronto Dominion Bank grew its position in TESARO by 244.6% in the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.